MENU
OCT 19, 2022 6:00 AM PDT

Keynote Presentation: A Newcastle Disease Virus-Based COVID-19 Vaccine with Live Q&A

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Vaccines against SARS-CoV-2 have been made in a record time. However, although the vaccines that have been deployed have clearly reduced the percentage of severe infections in countries where they have been widely used, many developing countries have problems to afford the purchase and/or distribution of approved vaccines. In addition, current vaccines provide with limited mucosal immunity to appropriately prevent infections. New efficacious and safe SARS-CoV-2 vaccines that could be manufactured locally in developing countries, that would not require ultra-congelation and that would induce infection-preventing mucosal immunity are desirable. We have been working in the development of such a vaccine based on a Newcastle disease virus (NDV) vector. This avian virus is widely used as live and inactivated vaccine in poultry against Newcastle disease, a potentially devastating avian disease. NDV inoculation in mammals results in abortive infection due to the induction of a robust local innate immune response that inhibits further virus replication while potentiating the induction of adaptive immune responses. NDV vaccines are manufactured using the same technology as most of the influenza virus vaccines, making it possible its production in most developing countries. We have generated NDV-based vaccines expressing a stabilized version of the S protein of SARS-CoV-2. These vaccines are stable at 2 degrees and provide protection against SARS-CoV-2 and its variants in animal models. NDV-based vaccines not only express the vaccine antigen in infected cells, but also incorporate the antigen into the virion, making it possible the use of either live or inactivated versions of the vaccine. Results from phase I clinical trials demonstrated lack of severe adverse events and very mild reactogenicity, as well as the induction of a robust T cell and neutralizing antibody response against SARS-CoV-2. Additional clinical trials have been initiated using live intranasal administration which has the potential to generate a more potent mucosal immunity for prevention of not only disease but also asymptomatic infections and transmission.

Learning Objectives:

1. Explain how mucosal immunity is required to prevent respiratory virus infections.

2. Discuss current COVID-19 vaccines and how they are highly effective in preventing severe disease, but less efficient in preventing reinfections.

3. Discuss how new generation of COVID-19 vaccines that prevent both severe disease and infection/transmission are desirable.
 


Show Resources
You May Also Like
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
NOV 09, 2022 8:00 AM PST
C.E. CREDITS
NOV 09, 2022 8:00 AM PST
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
Loading Comments...
Show Resources